Clinical trialPhase 1 / Phase 2Not yet recruiting
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants With Advanced Malignancies
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 23 April 2026
- Expected end
- 1 April 2028
- Enrollment
- 66 participants
- Sites
- 0
- Primary outcomes
- To characterize the safety and tolerability of RP-001 administered as monotherapy.
- Sponsor
- Industry
- Results posted
- No
- Last update
- 31 March 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Phase 1/2a Study of RP-001 in participants with Advanced Malignancies
Detailed description public domain (ClinicalTrials.gov)
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants with Advanced Malignancies